GlassScriptPhysician profile
Eli T Anderson
NPI 1053342634
$8,072.02
in general payments reported to CMS, 2019-2025
23 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $736 · 2021: $901 · 2022: $685 · 2023: $1,345 · 2024: $913 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,669.10 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Abbvie INC. | $1,344.69 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,126.04 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $818.31 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $602.09 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $521.18 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $444.44 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.14 | 2020-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $224.63 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.73 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $186.47 | 2019-2023 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $146.13 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $124.99 | 2019 | |
| Lundbeck LLC | $91.43 | 2020-2023 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $53.32 | 2023-2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.60 | 2025 | Cobenfy |
| Indivior INC. | $43.39 | 2023 | Perseris |
| Supernus Pharmaceuticals, INC. | $38.51 | 2023-2024 | Qelbree, Qelbree |
| Eisai INC. | $22.24 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.79 | 2019 | |
| Merck Sharp & Dohme LLC | $18.20 | 2020 | |
| Adlon Therapeutics L.P. | $13.83 | 2020 | |
| Medline Industries LP | $13.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.